Literature DB >> 26531733

Neurofibromatosis 1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like symptoms.

Waqar Waheed1, Muriel H Nathan2, Gilman B Allen3, Neil M Borden4, M Ali Babi1, Rup Tandan1.   

Abstract

A 37-year-old man with a known history of neurofibromatosis 1 (NF1) presented within 2 days of diarrhoeal illness followed by encephalopathy, facial twitching, hypoglycaemia, hypotension, tachycardia and low-grade fever. Examination showed multiple café-au-lait spots and neurofibromas over the trunk, arms and legs and receptive aphasia with right homonymous hemianopia, which resolved. Workup for cardiac, inflammatory and infectious aetiologies was unrevealing. A brain MRI showed gyral swelling with increased T2 fluid-attenuated inversion recovery signal and diffusion restriction in the left cerebral cortex. Neuroendocrine findings suggested panhypopituitarism with centrally derived adrenal insufficiency. Supportive treatment, hormone supplementation, antibiotics, antivirals and levetiracetam yielded clinical improvement. A follow-up brain MRI showed focal left parieto-occipital atrophy with findings of cortical laminar necrosis. In conclusion, we describe a case of NF1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like findings, hitherto unreported manifestations of NF1. Prompt recognition and treatment of these associated conditions can prevent devastating complications. 2015 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26531733      PMCID: PMC4654154          DOI: 10.1136/bcr-2015-210816

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  24 in total

Review 1.  Corticosteroid insufficiency in acutely ill patients.

Authors:  Mark S Cooper; Paul M Stewart
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

2.  Plexiform neurofibromas in children with neurofibromatosis type 1: frequency and associated clinical deficits.

Authors:  Rosa Nguyen; Lan Kluwe; Carsten Fuensterer; Michael Kentsch; Reinhard Edgar Friedrich; Victor-Felix Mautner
Journal:  J Pediatr       Date:  2011-05-31       Impact factor: 4.406

3.  Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions.

Authors:  R Vassilopoulou-Sellin; M J Klein; J K Slopis
Journal:  Pediatr Neurol       Date:  2000-05       Impact factor: 3.372

Review 4.  Clinical review 86: Euthyroid sick syndrome: is it a misnomer?

Authors:  I J Chopra
Journal:  J Clin Endocrinol Metab       Date:  1997-02       Impact factor: 5.958

5.  Two CGTCA motifs and a GHF1/Pit1 binding site mediate cAMP-dependent protein kinase A regulation of human growth hormone gene expression in rat anterior pituitary GC cells.

Authors:  A R Shepard; W Zhang; N L Eberhardt
Journal:  J Biol Chem       Date:  1994-01-21       Impact factor: 5.157

6.  Stroke in an infant prior to the development of manifestations of neurofibromatosis.

Authors:  L Hornstein; D Borchers
Journal:  Neurofibromatosis       Date:  1989

7.  [Pituitary adenoma associated with neurofibromatosis type 1: case report].

Authors:  Kazuhiko Kurozumi; Akira Tabuchi; Yasuhiro Ono; Takashi Tamiya; Takashi Ohmoto; Tomohisa Furuta; Shuji Hamasaki
Journal:  No Shinkei Geka       Date:  2002-07

8.  MR imaging of hypoglycemic encephalopathy: lesion distribution and prognosis prediction by diffusion-weighted imaging.

Authors:  Jeong-Hyun Ma; Young-Joo Kim; Won-Jong Yoo; Yon-Kwon Ihn; Jee-Young Kim; Ha-Hun Song; Bum-Soo Kim
Journal:  Neuroradiology       Date:  2009-06-17       Impact factor: 2.804

9.  Epilepsy in individuals with neurofibromatosis type 1.

Authors:  Adam P Ostendorf; David H Gutmann; Judith L Z Weisenberg
Journal:  Epilepsia       Date:  2013-08-29       Impact factor: 5.864

Review 10.  Acute symptomatic hypoglycaemia mimicking ischaemic stroke on imaging: a systemic review.

Authors:  Ai Wain Yong; Zoe Morris; Kirsten Shuler; Colin Smith; Joanna Wardlaw
Journal:  BMC Neurol       Date:  2012-11-21       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.